Lawrenceville, NJ, United States of America

Ralph Abraham


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 75(Granted Patents)


Company Filing History:


Years Active: 2005-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ralph Abraham: Innovator in Humanized Antibodies

Introduction

Ralph Abraham is a notable inventor based in Lawrenceville, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 2 patents to his name, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Abraham's latest patents include "Polynucleotides encoding humanized antibodies against human 4-1BB" and "Humanized antibodies against human 4-1BB." Both patents describe a humanized antibody that binds to human 4-1BB, facilitating its interaction with the human 4-1BB ligand. Notably, the antibody is characterized as an IgG4 antibody. Additionally, these patents provide methods for treating cancer by administering a therapeutically effective amount of the antibody to the subject.

Career Highlights

Ralph Abraham is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His work has the potential to impact cancer therapies significantly, showcasing his dedication to improving patient outcomes.

Collaborations

Abraham collaborates with esteemed colleagues, including Maria Jure Kunkel and Subinay Ganguly. Their combined expertise contributes to the innovative research being conducted at Bristol-Myers Squibb.

Conclusion

Ralph Abraham's contributions to the field of biotechnology, particularly in the development of humanized antibodies, highlight his role as a key innovator. His patents and ongoing work at Bristol-Myers Squibb reflect his commitment to advancing cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…